ISSN 1470-3947 (print)
ISSN 1479-6848 (online)

Searchable abstracts of presentations at key conferences in endocrinology

Published by BioScientifica
Endocrine Abstracts (2010) 22 P74 
|

Delayed puberty and bone turnover biochemical markers

Marian Bistriceanu1, Iulia Bistriceanu2, Magda Elvira Preda2, Simona Bondari1, Aurora Covei2 & Liliana Putinelu3

Author affiliations

Background: Delayed puberty means the absence of secondary sexual characters until the age of 16 or the lack of puberty development until the limit of +2DS regarding the age when the puberty normally begins at considered population. Considering the major ethiological factor implied in delayed puberty, three mechanisms can be distinguished: hypothalamic, hypophyseal and gonadal. Osteoporosis depends mainly on the deficiency of one or of all sexual hormones, arised during the ontogenesis process.

Methods: We enrolled 26 cases of delayed puberty, aged 12–35, of which 14 cases (53.85%) of hypergonadotropic hypogonadism (female Turner syndrome – 10 cases; Klinefelter – four cases) and 12 cases (46.15%) of hypogonadotropic hypogonadism (hypophyseal dwarfism with sexual infantilism – three cases; functional adipose-genital syndrome – seven cases; tumor-like hypophyseal insufficiency – two cases). Plasmatic level of the two markers of bone turnover (osteocalcine and CrossLap) was evaluated by ELISA method. Dual absorption with X-rays assesed bone mineral density.

Results: DEXA identified, 10 cases (38.46%) of osteoporosis, where the osteocalcine values (29.4–112.96 ng/ml) and CrossLap (0.197–1.768 ng/ml) were comparable with those of women in postmenopausal period, six cases (23.08%) of osteopenia, and 10 cases (38.46%) of T score value and biochemical markers in normal range.

Conclusions: Our study suggests two major objectives of therapy for existent osteoporosis/osteopenia at delayed puberty pacients: precocious diagnosis of gonadal insufficiency, in to apply some prophylaxis measures for bone modifications beginning from pre-puberty, thus insuring the stabilization or increasing bone mass corresponding to sex and age; therapy associates estro-progestative/ androgenic substitution and antiresorbtion or proformation medication.

This Issue/Conference

Article tools

My recently viewed abstracts

My recent searches